Glutamatergic neurotransmission,
depression and antidepressants
by
Ferrero A, Cereseto M.
Farmaceutico, Becario UBA, Junin.
aferrero@ffyb.uba.ar
Vertex. 2004 Jun-Aug;15(56):91-8

ABSTRACT

Depression is a psychiatric disorder that affects 20% of the population. Despite the efforts aimed to identify the mechanisms underlying its behavioral and affective symptoms, no consensus has been reached. In the last years two new theories, the glutamatergic and the genomic ones, have been proposed. Upon the first, the exposition to stressful stimuli increases hippocampal glutamatergic neurotransmission and triggers excitotoxic changes. The second one postulates that depression is closely correlated with neuronal atrophy due to a decrease in BDNF. The aim of this work is to review recent findings about the glutamatergic neurotransmission and its implication in animal models of depression, depressed patients and in both conditions after the antidepressant treatment. We also tried to identify possible links between these observations and the genomic theory.

BDNF
NMDA
Riluzole
Monoamines
21st Century
Noradrenaline
Neurotrophins
NMDA antagonists
New antidepressants
Glutamate and GABA
Antidepressant augmentation strategies

Refs
HOME
HedWeb
Future Opioids
BLTC Research
MDMA/Ectsasy
Paradise-Engineering
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family